Literature DB >> 15239144

National Polyp Study data: evidence for regression of adenomas.

Franka Loeve1, Rob Boer, Ann G Zauber, Marjolein Van Ballegooijen, Gerrit J Van Oortmarssen, Sidney J Winawer, J Dik F Habbema.   

Abstract

The data of the National Polyp Study, a large longitudinal study on surveillance of adenoma patients, is used for testing assumptions on the adenoma-carcinoma sequence. The observed adenoma and colorectal cancer incidence in the National Polyp Study were compared with the simulated outcomes of the MISCAN-COLON model of epidemiology and control of colorectal cancer for the U.S. population based on expert opinion. Variants of this model were explored in order to identify assumptions on the adenoma-carcinoma sequence that are consistent with the study observations. The high observed adenoma detection rates at surveillance and low observed colorectal cancer incidence in the National Polyp Study could only be explained by assuming a high incidence rate of adenomas accompanied by regression of adenomas. The National Polyp Study data suggest that adenoma prevalence results from a dynamic process of both formation as well as regression of adenomas. This lowers the expectations for the effects of colorectal cancer screening strategies that focus on adenoma detection. Copyright 2004 Wiley-Liss, Inc.

Entities:  

Mesh:

Year:  2004        PMID: 15239144     DOI: 10.1002/ijc.20277

Source DB:  PubMed          Journal:  Int J Cancer        ISSN: 0020-7136            Impact factor:   7.396


  50 in total

1.  Probability model for estimating colorectal polyp progression rates.

Authors:  Chaitra Gopalappa; Selen Aydogan-Cremaschi; Tapas K Das; Seza Orcun
Journal:  Health Care Manag Sci       Date:  2010-10-05

2.  Implementation of colonoscopic process measures: does it improve quality?

Authors:  Theodor Asgeirsson; Anthony J Senagore; Nadav Dujovny; Rebecca Hoedema; Donald Kim; Heather Slay; Martin Luchtefeld
Journal:  Surg Endosc       Date:  2010-08-19       Impact factor: 4.584

3.  The cost-effectiveness of screening for colorectal cancer.

Authors:  Jennifer J Telford; Adrian R Levy; Jennifer C Sambrook; Denise Zou; Robert A Enns
Journal:  CMAJ       Date:  2010-07-12       Impact factor: 8.262

Review 4.  Polyp size measurement at CT colonography: what do we know and what do we need to know?

Authors:  Ronald M Summers
Journal:  Radiology       Date:  2010-06       Impact factor: 11.105

5.  Next-generation stool DNA test accurately detects colorectal cancer and large adenomas.

Authors:  David A Ahlquist; Hongzhi Zou; Michael Domanico; Douglas W Mahoney; Tracy C Yab; William R Taylor; Malinda L Butz; Stephen N Thibodeau; Linda Rabeneck; Lawrence F Paszat; Kenneth W Kinzler; Bert Vogelstein; Niels Chr Bjerregaard; Søren Laurberg; Henrik Toft Sørensen; Barry M Berger; Graham P Lidgard
Journal:  Gastroenterology       Date:  2011-11-04       Impact factor: 22.682

6.  Colon Tumors with the Simultaneous Induction of Driver Mutations in APC, KRAS, and PIK3CA Still Progress through the Adenoma-to-carcinoma Sequence.

Authors:  Jamie N Hadac; Alyssa A Leystra; Terrah J Paul Olson; Molly E Maher; Susan N Payne; Alexander E Yueh; Alexander R Schwartz; Dawn M Albrecht; Linda Clipson; Cheri A Pasch; Kristina A Matkowskyj; Richard B Halberg; Dustin A Deming
Journal:  Cancer Prev Res (Phila)       Date:  2015-08-14

7.  Sporadic adenomatous polyp regression with exisulind is effective but toxic: a randomised, double blind, placebo controlled, dose-response study.

Authors:  N Arber; S Kuwada; M Leshno; R Sjodahl; R Hultcrantz; D Rex
Journal:  Gut       Date:  2005-09-08       Impact factor: 23.059

8.  State disparities in colorectal cancer rates: Contributions of risk factors, screening, and survival differences.

Authors:  Iris Lansdorp-Vogelaar; S Lucas Goede; Jiemin Ma; Wu Xiau-Cheng; Karen Pawlish; Marjolein van Ballegooijen; Ahmedin Jemal
Journal:  Cancer       Date:  2015-07-06       Impact factor: 6.860

9.  Cost-effectiveness of High-performance Biomarker Tests vs Fecal Immunochemical Test for Noninvasive Colorectal Cancer Screening.

Authors:  Iris Lansdorp-Vogelaar; S Lucas Goede; Linda J W Bosch; Veerle Melotte; Beatriz Carvalho; Manon van Engeland; Gerrit A Meijer; Harry J de Koning; Marjolein van Ballegooijen
Journal:  Clin Gastroenterol Hepatol       Date:  2017-07-18       Impact factor: 11.382

10.  Effect of rising chemotherapy costs on the cost savings of colorectal cancer screening.

Authors:  Iris Lansdorp-Vogelaar; Marjolein van Ballegooijen; Ann G Zauber; J Dik F Habbema; Ernst J Kuipers
Journal:  J Natl Cancer Inst       Date:  2009-09-24       Impact factor: 13.506

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.